Who
Jeffrey G. Black
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Exagen; SVP & Chief Financial Officer, Standard BioTools; Chief Financial Officer, Apollo Endosurgery; EVP & CFO, Alphatec Holdings; Sr. Vice President & CFO, Verenium.
In numbers
- Trades disclosed
- 106
- Buys
- 13
- Sells
- 9
- Bought
- $740K
- Sold
- $1.2M
- Companies
- 5
- Companies where not an officer
- 0
- First trade
- 20 Dec 2008
- Last trade
- 1 Sep 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 2 Sep 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $149K20,614 at $7.22 | filing |
| 1 Sep 2026filed 2 Sep 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $4,7401,571 at $3.02 | filing |
| 1 Sep 2026filed 2 Sep 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $149K20,614 at $7.22 | filing |
| 1 Sep 2026filed 2 Sep 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $4,7441,571 at $3.02 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $237K75,000 at $3.16 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | $158K50,000 at $3.16 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | $158K50,000 at $3.16 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $237K75,000 at $3.16 | filing |
| 27 Feb 2026filed 16 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $4,6491,511 at $3.08 | filing |
| 27 Feb 2026filed 16 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $4,6541,511 at $3.08 | filing |
| 24 Feb 2026filed 25 Feb 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $5,7181,584 at $3.61 | filing |
| 24 Feb 2026filed 25 Feb 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $5,7181,584 at $3.61 | filing |
| 2 Sep 2025filed 4 Sep 2025 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $200K20,466 at $9.79 | filing |
| 21 Feb 2025filed 25 Feb 2025 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | $36K10,000 at $3.58 | filing |
| 21 Feb 2025filed 25 Feb 2025 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 15 Nov 2024filed 19 Nov 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Bought | $66K22,298 at $2.98 | filing |
| 1 Sep 2024filed 4 Sep 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 20 Aug 2024filed 5 Sep 2024 | LAB Standard BioToolsLife-science tools | SEC FORM 4 Code F | $13K6,690 at $1.91 | filing |
| 15 Aug 2024filed 19 Aug 2024 | LAB Standard BioToolsoption or derivative · Life-science tools | SEC FORM 4 Code M | —13,157 at $0.00 | filing |
| 15 Aug 2024filed 19 Aug 2024 | LAB Standard BioToolsLife-science tools | SEC FORM 4 Code M | —13,157 at $0.00 | filing |
News
Canaccord Genuity Group Issues Positive Forecast for Exagen (NASDAQ:XGN) Stock PriceXGN · themarketsdaily.com · 19 Oct 2026Centene (NYSE:CNC) vs. Exagen (NASDAQ:XGN) Head to Head SurveyXGN · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Jeffrey G. Black; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.